BeiGene, a Beijing novel oncology company, will collaborate with New York’s SpringWorks Therapeutics, combining BeiGene’s RAF inhibitor with SpringWorks’ MEK inhibitor to treat patients with advanced solid tumors. BeiGene will be in charge of the initial Phase I global trial, though the two companies will split the costs evenly. SpringWorks will be responsible for a fixed-dose formulation of the combination therapy.
Source: China Biotoday
